Prostate stem cell antigen single nucleotide polymorphisms influence risk of estrogen receptor negative breast cancer in korean females

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 1, 2012, Pages 41-48

  Kim, Sook Young ^a   Yoo, Jae Young ^a   Shin, Aesun ^b   Kim, Yeonju ^c,e   Lee, Eun Sook ^d   Lee, Yeon Su ^a  

^a Cancer Genomics Branch   (South Korea)

^b Molecular Epidemiology Branch   (South Korea)

^c Cancer Early Detection Branch   (South Korea)

^d National Cancer Center   (South Korea)

^e UNIVERSITY OF HAWAII CANCER CENTER   (United States)

Author keywords

8q24; Biomarker; Breast cancer; Polymorphism; PSCA

Indexed keywords

DNA; ESTROGEN RECEPTOR; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; PSCA PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR PROTEIN;

ARTICLE; BREAST TUMOR; CASE CONTROL STUDY; COMPARATIVE STUDY; FEMALE; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HUMAN; MASS SPECTROMETRY; METABOLISM; POLYMERASE CHAIN REACTION; PREMENOPAUSE; PROGNOSIS; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SOUTH KOREA;

ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CASE-CONTROL STUDIES; DNA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GPI-LINKED PROTEINS; HUMANS; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PREMENOPAUSE; PROGNOSIS; RECEPTORS, ESTROGEN; REPUBLIC OF KOREA; RISK FACTORS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84864872630     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.1.041     Document Type: Article

References (41)

1. AleAhmad S, Casey G, Sweeney P, et al (2009). Prostate stem cell antigen DNA vaccination breaks tolerance to self-antigen and inhibits prostate cancer growth. Mol Ther, 17, 1101-8.
2. Ahn SH (2004). Clinical characteristics of breast cancer patients in Korea in 2000. Arch Surg, 139, 27-30, discussion 1.
3. Benson JR, Jatoi I, Keisch M, et al. (2009). Early breast cancer. Lancet, 373, 1463-79.
4. Berndt SI, Potter JD, Hazra A, et al. (2008). Pooled analysis of genetic variation at chromosome 8q24 and colorectal neoplasia risk. Hum Mol Genet, 17, 2665-72.
5. Buck MB, Fritz P, Dippon J, et al. (2004). Prognostic significance of transforming growth factor beta receptor II in estrogen receptor-negative breast cancer patients. Clin Cancer Res, 10, 491-8.
6. Chen JQ, Brown TR, Russo J (2009). Regulation of energy metabolism pathways by estrogens and estrogenic chemicals and potential implications in obesity associated with increased exposure to endocrine disruptors. Biochim Biophys Acta, 1793, 1128-43.
7. Chu LW, Meyer TE, Li Q, et al. (2010). Association between genetic variants in the 8q24 cancer risk regions and circulating levels of androgens and sex hormone-binding globulin. Cancer Epidemiol Biomarkers Prev, 19, 1848-54.
8. Cianfrocca M, Gradishar W (2009). New molecular classifications of breast cancer. CA Cancer J Clin, 59, 303-13.
9. Coffey DS (2001). Similarities of prostate and breast cancer: Evolution, diet, and estrogens. Urology, 57, 31-8.
10. Czajka-Oraniec I, Simpson ER (2010). Aromatase research and its clinical significance. Endokrynol Pol, 61, 126-34.
11. Ferlay J, Shin HR, Bray F, et al. (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917.
12. Fletcher O, Johnson N, Gibson L, et al. (2008). Association of genetic variants at 8q24 with breast cancer risk. Cancer Epidemiol Biomarkers Prev, 17, 702-5.
13. Frasor J, Danes JM, Komm B, et al. (2003). Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology, 144, 4562-74.
14. Garcia-Closas M, Chanock S (2008). Genetic susceptibility loci for breast cancer by estrogen receptor status. Clin Cancer Res, 14, 8000-9.
15. Gluz O, Liedtke C, Gottschalk N, et al. (2009). Triple-negative breast cancer--current status and future directions. Ann Oncol, 20, 1913-27.
16. Habel LA, Capra AM, Oestreicher N, et al. (2007). Mammographic density in a multiethnic cohort. Menopause, 14, 891-9.
17. Han JS, Cao D, Molberg KH, et al. (2011). Hormone receptor status rather than HER2 status is significantly associated with increased Ki-67 and p53 expression in triple-negative breast carcinomas, and high expression of Ki-67 but not p53 is significantly associated with axillary nodal metastasis in triple-negative and high-grade non-triple-negative breast carcinomas. Am J Clin Pathol, 135, 230-7.
18. Imyanitov EN (2009). Gene polymorphisms, apoptotic capacity and cancer risk. Hum Genet, 125, 239-46.
19. Jung KW, Park S, Kong HJ, et al. (2011). Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008. Cancer Res Treat, 43, 1-11.
20. Kim BK, Lee JW, Park PJ, et al. (2009). The multiplex bead array approach to identifying serum biomarkers associated with breast cancer. Breast Cancer Res, 11, R22.
21. Li J, Humphreys K, Heikkinen T, et al. (2010). A combined analysis of genome-wide association studies in breast cancer. Breast Cancer Res Treat.
22. Lopez-Otin C, Diamandis EP (1998). Breast and prostate cancer: an analysis of common epidemiological, genetic, and biochemical features. Endocr Rev, 19, 365-96.
23. Matera L (2010). The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer. Cancer Treat Rev, 36, 131-41.
24. Matsuo K, Tajima K, Suzuki T, et al. (2009). Association of prostate stem cell antigen gene polymorphisms with the risk of stomach cancer in Japanese. Int J Cancer, 125, 1961-4.
25. Offit K, Robson ME (2010). New pharmacogenomic paradigm in breast cancer treatment. J Clin Oncol, 28, 4665-6.
26. Onay VU, Briollais L, Knight JA, et al. (2006). SNP-SNP interactions in breast cancer susceptibility. BMC Cancer, 6, 114.
27. Orlando L, Schiavone P, Fedele P, et al. (2010). Molecularly targeted endocrine therapies for breast cancer. Cancer Treat Rev, 36 Suppl 3, S67-71.
28. Ozet A, Yavuz AA, Komurcu S, et al. (2000). Bilateral male breast cancer and prostate cancer: a case report. Jpn J Clin Oncol, 30, 188-90.
29. Raff AB, Gray A, Kast WM (2009). Prostate stem cell antigen: a prospective therapeutic and diagnostic target. Cancer Lett, 277, 126-32.
30. Reiter RE, Gu Z, Watabe T, et al. (1998). Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A, 95, 1735-40.
31. Rochefort H, Glondu M, Sahla ME, et al. (2003). How to target estrogen receptor-negative breast cancer. Endocr Relat Cancer, 10, 261-6.
32. Rugo HS (2008). The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors. Ann Oncol, 19, 16-27.
33. Sakamoto H, Yoshimura K, Saeki N, et al (2008). Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat Genet, 40, 730-40.
34. Smith LF (2007). Palpable cancer of the breast and negative mammography: the ongoing dilemma. J Surg Oncol, 96, 451-2.
35. Thomas G, Jacobs KB, Kraft P, et al. (2009). A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet, 41, 579-84.
36. Uray IP, Brown PH (2011). Chemoprevention of hormone receptor-negative breast cancer: new approaches needed. Recent Results Cancer Res, 188, 147-62.
37. Wiechec E, Hansen LL (2009). The effect of genetic variability on drug response in conventional breast cancer treatment. Eur J Pharmacol, 625, 122-30.
38. Williams C, Brunskill S, Altman D, et al. (2006). Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy. Health Technol Assess, 10, iii-iv, ix-xi, 1-204.
39. Wu X, Ye Y, Kiemeney LA, et al. (2009). Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet, 41, 991-5.
40. Yang X, Lippman ME (1999). BRCA1 and BRCA2 in breast cancer. Breast Cancer Res Treat, 54, 1-10.
41. Yeager M, Xiao N, Hayes RB, et al. (2008). Comprehensive resequence analysis of a 136 kb region of human chromosome 8q24 associated with prostate and colon cancers. Hum Genet, 124, 161-70.